Novavax aims for two billion COVID-19 vaccine doses with expanded Serum Institute deal




  • In Business
  • 2020-09-15 11:25:03Z
  • By Reuters
Novavax aims for two billion COVID-19 vaccine doses with expanded Serum Institute deal
Novavax aims for two billion COVID-19 vaccine doses with expanded Serum Institute deal  

(Reuters) - Novavax Inc is doubling its COVID-19 vaccine manufacturing capacity to two billion doses under an agreement with Serum Institute of India, the U.S. company said on Tuesday.

In August, Novavax signed a deal with Serum Institute, the world's largest producer of vaccines, to produce a minimum of one billion doses of its vaccine candidate for low-and middle-income countries and India.

As part of the expanded agreement, Serum Institute will also manufacture the antigen component of the vaccine, which is dubbed NVX‑CoV2373.

The U.S. company's vaccine is in mid-stage trials after an early-stage trial showed it produced high levels of antibodies against the novel coronavirus.

Other drugmakers such as Pfizer Inc and Moderna Inc have already begun large late-stage studies of their experimental vaccines.


(Reporting by Aakriti Bhalla in Bengaluru; Editing by Saumyadeb Chakrabarty)

COMMENTS

More Related News

Exclusive: Top adviser steps aside from FDA COVID-19 vaccine reviews over potential conflict
Exclusive: Top adviser steps aside from FDA COVID-19 vaccine reviews over potential conflict
  • US
  • 2020-09-23 21:40:20Z

Hana El Sahly, associate professor of virology and microbiology at Baylor College of Medicine in Houston, last year became chairwoman of the FDA's Vaccines and Related Biological Products Advisory Committee - the panel of outside experts that will make recommendations on whether coronavirus vaccines should be approved. In July, however, El Sahly was named one of three lead investigators for Moderna's late-stage COVID-19 vaccine trial, creating a potential conflict of interest. Moderna has said it could have enough data to show whether its vaccine is safe and effective as soon as November.

EU close to concluding preliminary talks with Novavax on COVID vaccine supply: source
EU close to concluding preliminary talks with Novavax on COVID vaccine supply: source
  • US
  • 2020-09-23 16:20:23Z

Brussels is close to wrapping up preliminary talks with U.S. vaccine maker Novavax for its potential COVID-19 shot, an EU source involved in the negotiations said, as the bloc ramps up its push in the global race to secure supplies. It would bring doses potentially available to EU countries to more than 2 billion. "We are at an advanced stage in talks with Novavax," the EU senior official said, who declined to be identified as negotiations are confidential.

J&J kicks off final study of single-shot COVID-19 vaccine in 60,000 volunteers
J&J kicks off final study of single-shot COVID-19 vaccine in 60,000 volunteers

Johnson & Johnson on Wednesday kicked off a final 60,000-person trial of a single-shot COVID-19 vaccine that potentially would simplify distribution of millions of doses compared with leading rivals using two doses. The company expects results of the Phase III trial by year end or early next year, Dr. Paul Stoffels, J&J's chief scientific officer, said in a joint press conference with officials from the National Institutes of Health and the Trump administration. Rival vaccines from Moderna Inc , Pfizer Inc and AstraZeneca all require two shots separated by several weeks, which make them much more difficult to administer.

U.S. FDA to tighten coronavirus vaccine trial standards ahead of November election - paper
U.S. FDA to tighten coronavirus vaccine trial standards ahead of November election - paper
  • US
  • 2020-09-22 20:08:57Z

The agency is issuing the guidance to boost transparency and public trust as health experts have become increasingly concerned that the Trump administration might be interfering in the approval process, the newspaper said. According to the report, the FDA is expected to ask vaccine manufacturers seeking an emergency authorization to follow trial participants for a median of at least two months after they receive a second vaccine shot. Few vaccine developers were expected to have definitive trial results before the election, but Pfizer Inc has said it might have data for the FDA to review by late October - although that timetable could slip with the new guidance.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business